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Case ReportsHemoconcentration in ex vivo lung perfusion: A case report of a novel
technique used in clinical lung transplantationAndreas Wallinder, MD,a,b Christoffer Hansson, MSc,c and G€oran Dellgren, MD, PhD,a,b,d Gothenburg,
SwedenReconditioning of initially rejected donor lungs during
ex vivo lung perfusion (EVLP) may increase the number
of patients treated with a lung transplantation.1-3
Multiorgan donors often suffer from circulatory instability
and therefore may be treated with massive crystalloid
fluid infusions, which can result in pulmonary edema.
EVLP of the donor lungs with a hyperoncotic perfusate
theoretically can decrease the lung water content by
absorbing alveolar and interstitial edema.4 The oncoticFIGURE 1. A, Schematic of the EVLP unit. The blood enters the open reservoi
drawn from the pulmonary vein outflow and from a port after the oxygenator, w
allows for intermittent hemoconcentration. Pulmonary artery (PA). B, EVLP data
oncotic pressure of the perfusate. HCU, Heater-cooler unit; PVR, pulmonary v
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fusion as edema is absorbed. Eventually, the oncotic pres-
sure in the perfusate may equal the oncotic pressure in the
interstitial space and, at that time, the perfusat has lost its
absorbing capacity. It has been suggested that the perfusate
should be replaced intermittently with new solution,5 but
instead we used hemoconcentration of the ex vivo lung per-
fusate to preserve the high oncotic pressure.
MATERIALS AND METHODS
Perfusion (VivolineLS1;VivolineMedical, Lund, Sweden) of an initially
rejected donor lung was performed with Steen solution (XVIVO perfusion,
Gothenburg, Sweden) mixed with red blood cells to a hematocrit of 10% to
15%. A filter for hemoconcentration (HemocorHPH400;Medivators,Min-
neapolis, Minn) was connected to the EVLP tubing as a shunt after the roller
pump (Figure 1, A). Hemoconcentration was performed intermittently dur-
ing the EVLP procedure. The lungs were otherwise treated according to our
regular protocol for EVLP.2
RESULTS
One pair of donor lungs initially rejected for transplanta-
tion because of an infiltrate on chest radiograph and inferior
arterial oxygen tension (PaO2)/inspired oxygen fractionr via the remnant of the left atrium (LA). Samples for blood gas analyses are
here drugs also can be administered. The clamp on the hemofilter circuit
with volume of ultrafiltrate, pulmonary vascular resistance, osmolality, and
ascular resistance; EVLP, ex vivo lung perfusion.
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TABLE 1. EVLP data
Time, min 0 30 60 90 120 150 180 210
Hemofiltration, mL 0 50 350 350 350 350 550 550
Temperature, C — 17.4 35.0 36.5 36.5 36.5 36.5 31
Pulmonary artery flow, L/min 0 3.4 4.4 4.4 4.4 4.4 4.4 4.0
PVR, dyn$s$cm5 0 350 300 310 274 310 330 300
Oncotic pressure in perfusate, mm Hg 32 30.4 37.8 35.9 37.8 37.9 42.4 43.4
Osmolality, mOsm/kg N/A 333 336 363 360 357 359 374
N/A, Not applicable or not available; PVR, pulmonary vascular resistance.
Case Reports(FIO2) (10 kPa) was subjected to ex vivo reconditioning. The
lungs were heavy with fluid and weighed 1150 g before be-
ing connected to the EVLP unit. EVLP was performed ac-
cording to our regular protocol with reconditioning
followed by functional evaluation. During perfusion the
shunt to the hemofilter was opened intermittently and 550
mL of fluid was dialyzed from the perfusate. Oncotic pres-
sure, osmolality, and pulmonary vascular resistancewere re-
corded (Table 1). The donor lungs improved their
oxygenation capacity to a PaO2/FIO2 of 53.7 kPa at the end
of the EVLP. During evaluation, hemodynamic (flow, pul-
monary vascular resistance, pressure) parameters were sta-
ble (Figure 1, B). The hematocrit level increased from
10.8% to 11.4%. A weight loss of 200 g was registered.
The lungswere deemed suitable for transplantation and a pa-
tient from the regular waiting list underwent a double lung
transplantation. The recipient was extubated after 20 hours
and the PaO2 was 17.4 kPa at 4 liters of oxygen on postoper-
ative day 1. Primary graft dysfunctionwas grade 0 at both 24
and 72 hours. The patient was discharged from the hospital
on postoperative day 26 and is still doing well. The patient
completed the 9-month follow-up evaluation and has had
stable lung function parameters on spirometry during the en-
tire postoperative period.
CONCLUSIONS
The hyperoncotic properties of the EVLP perfusate theo-
retically will decrease the lung water content. Despite this,
we previously observed increased lung weight after EVLP
in a number of cases.2 Replacement of the expensive hyper-
oncotic solution has been suggested but the effect of thisma-
neuver seems unpredictable and no measurements of the
oncotic effect have been published.5 When a hemofilter is
included in the EVLP circuit the oncotic pressure can beThe Journal of Thoracic and Camaintained or increased during EVLP, but as shown in
Figure 1, B, the effect of the hemoconcentration procedure
is delayed and unpredictable. Therefore, dialysis must be
performed cautiously with continuous evaluation of EVLP
parameters and ideally adjusted after intermittent sampling
of the oncotic pressure. It is not possible to determine how
much the improvement in lung fuction during EVLP
depended on the hemoconcentration. However, when com-
pared with edematous lungs previously evaluated, which
in some cases gained weigh during EVLP, the weight loss
of the lungs in this case might be an indicator of reduced
lung edema.
As global demand for donor lungs increases and the num-
ber of multiorgan donors remains constant, everything must
be done to increase the yield of lungs used. Novel ap-
proaches and the development of perfusion techniques are
needed to optimize EVLP further. Hemoconcentration dur-
ing EVLP is a promising method that we will continue to
evaluate, especially in very edematous lungs, which may
require EVLP with longer duration.References
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